Trial · NCT01320722
Results by group75
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 75
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D] | Vitamin D | 35.7 | Standard Deviation 47.7 | mL/min per 1.73 m^2 | |
| Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance [Vitamin D] | Placebo- Vitamin D | 35.9 | Standard Deviation 26.2 | mL/min per 1.73 m^2 | |
| Plasma Renin Activity (PRA) [Vitamin D] | Vitamin D | 0.36 | Standard Deviation 0.44 | ng/mL per hour | |
| Plasma Renin Activity (PRA) [Vitamin D] | Placebo- Vitamin D | 0.44 | Standard Deviation 0.8 | ng/mL per hour | |
| Angiotensin II (ATII) Concentration [Vitamin D] | Vitamin D | 19.5 | Standard Deviation 4.4 | pg/mL | |
| Angiotensin II (ATII) Concentration [Vitamin D] | Placebo- Vitamin D | 19.7 | Standard Deviation 7.1 | pg/mL | |
| Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid] | Probenecid | 33 | Inter-Quartile Range 12 to 72 | mL/min per 1.73 m^2 | |
| Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid] | Allopurinol | 36 | Inter-Quartile Range 17 to 55 | mL/min per 1.73 m^2 | |
| Change in Renal Plasma Flow (RPF) Response to Captopril in High Sodium Balance [Uric Acid] | Placebo- Uric Acid | 30 | Inter-Quartile Range -1 to 48 | mL/min per 1.73 m^2 | |
| Plasma Renin Activity (PRA) [Uric Acid] | Probenecid | 0.4 | Inter-Quartile Range 0.2 to 0.7 | ng/mL per hour | |
| Plasma Renin Activity (PRA) [Uric Acid] | Allopurinol | 0.3 | Inter-Quartile Range 0.2 to 0.5 | ng/mL per hour | |
| Plasma Renin Activity (PRA) [Uric Acid] | Placebo- Uric Acid | 0.2 | Inter-Quartile Range 0.1 to 0.6 | ng/mL per hour | |
| Angiotensin II (ATII) Concentration [Uric Acid] | Probenecid | 20.3 | Inter-Quartile Range 18.5 to 22.7 | pg/mL | |
| Angiotensin II (ATII) Concentration [Uric Acid] | Allopurinol | 21.4 | Inter-Quartile Range 18.2 to 24.4 | pg/mL | |
| Angiotensin II (ATII) Concentration [Uric Acid] | Placebo- Uric Acid | 19.1 | Inter-Quartile Range 17.0 to 21.5 | pg/mL | |
| Change in Endothelium-Dependent Vasodilation (EDV) | Vitamin D | Baseline | 6.3 | Standard Deviation 3.6 | percent of brachial luminal diameter |
| Change in Endothelium-Dependent Vasodilation (EDV) | Placebo- Vitamin D | Baseline | 7.9 | Standard Deviation 4.7 | percent of brachial luminal diameter |
| Change in Endothelium-Dependent Vasodilation (EDV) | Probenecid | Baseline | 7.4 | Standard Deviation 5.1 | percent of brachial luminal diameter |
| Change in Endothelium-Dependent Vasodilation (EDV) | Allopurinol | Baseline | 7.6 | Standard Deviation 6.0 | percent of brachial luminal diameter |
| Change in Endothelium-Dependent Vasodilation (EDV) | Placebo- Uric Acid | Baseline | 6.5 | Standard Deviation 3.8 | percent of brachial luminal diameter |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01320722/results